Introduction
Endoscopic submucosal dissection (ESD) is a minimally invasive procedure used to remove early-stage gastrointestinal (GI) tumors. It is a safe and effective alternative to surgery, and it has been shown to improve patient outcomes.
The ESD market is expected to grow at a compound annual growth rate (CAGR) of 6.9% from 2023 to 2030. This growth is being driven by a number of factors, including the increasing prevalence of GI diseases, the rising cost of surgery, and the growing demand for minimally invasive procedures.
Market Segmentation
The ESD market can be segmented by product, indication, end user, and region.
- By product: The market for ESD products is segmented into grasps, clips, gastroscopes, and colonoscopes. Grasps are used to hold the tumor in place during the procedure, clips are used to close the incision after the tumor is removed, gastroscopes and colonoscopes are used to visualize the tumor and guide the procedure.
- By indication: The market for ESD indications is segmented into esophageal cancer, stomach cancer, and colon cancer. Esophageal cancer is the most common indication for ESD, followed by stomach cancer and colon cancer.
- By end user: The market for ESD end users is segmented into hospitals, ambulatory surgical centers, and specialty clinics. Hospitals are the largest end user of ESD, followed by ambulatory surgical centers and specialty clinics.
- By region: The market for ESD is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the largest market for ESD, followed by Europe, Asia Pacific, and RoW.
Market Drivers and Trends
The ESD market is being driven by a number of factors, including:
- The increasing prevalence of GI diseases: The prevalence of GI diseases, such as esophageal cancer, stomach cancer, and colon cancer, is increasing worldwide. This is due to a number of factors, including aging populations, changing diets, and increasing obesity rates.
- The rising cost of surgery: Surgery is a costly procedure, and it can be associated with a number of risks. ESD is a less expensive and less risky alternative to surgery.
- The growing demand for minimally invasive procedures: Patients are increasingly demanding minimally invasive procedures, such as ESD. These procedures are associated with shorter recovery times and lower risk of complications.
Market Challenges
The ESD market faces a number of challenges, including:
The need for specialized training: ESD is a complex procedure, and it requires specialized training. This can limit the number of physicians who are qualified to perform ESD.
The risk of complications: ESD is a minimally invasive procedure, but it can still be associated with a number of risks, such as bleeding, perforation, and infection.
The need for further research: More research is needed to improve the safety and efficacy of ESD.
Market Opportunities
The ESD market offers a number of opportunities, including:
The growing market for GI cancer treatment: The market for GI cancer treatment is growing, and ESD is a promising treatment option for early-stage GI tumors.
The development of new ESD technologies: New technologies, such as robotic ESD, are being developed to improve the safety and efficacy of ESD.
The expansion of ESD into new markets: ESD is still a relatively new procedure, and it has the potential to be expanded into new markets, such as Asia Pacific and RoW.
Conclusion
The ESD market is expected to grow at a CAGR of 6.9% from 2023 to 2030. This growth is being driven by a number of factors, including the increasing prevalence of GI diseases, the rising cost of surgery, and the growing demand for minimally invasive procedures. The ESD market offers a number of opportunities, including the growing market for GI cancer treatment, the development of new ESD technologies, and the expansion of ESD into new markets.
For more information about the report and to request a sample copy, please visit
Contact Us:
John.M
Business Consultant
john.m@pharmanucleus.com
Support: +44 (0)20 8470 4967
https://www.pharmanucleus.com/
About Pharmanucleus
Pharma Nucleus is a market research company that provides clients access to custom, syndicated reports and consulting on one platform. As a company with rich knowledge in analysis and research across healthcare domains, such as pharma, medical device and biotechnology. Insights derived from Pharma Nucleus help life sciences and other healthcare organizations accelerate the launch, development, and dissemination of life-saving therapies, navigate significant attention with key opinion leaders, and help ensure equitable access to healthcare services.